drugset / Trial / NCT00737971

Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema

NCT00737971

Phase 4 Completed 142 enrolled Rubens Belfort Jr.
RandomizedParallel-groupDouble-blindTreatment

Summary

Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema

Timeline

Start
2008-08
Primary completion
2012-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 0.05 ml Intravitreal
Comparator Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Comparator Triamcinolone Other / unclassified 0.1 ml Intravitreal
Comparator Triamcinolone Other / unclassified 4 mg Intravitreal